Integrated PET/MR for Alzheimer’s Disease

PET/MR imaging is used for monitoring and assessing brain function, molecular information and metabolism. Combined PET/MR imaging has improved the diagnostic power for Alzheimer’s disease, enabling early and accurate diagnoses and better elimination of differential diagnoses. Combining PET and MR scans is a convenient option for patients which also lowers the amount of radiation they are exposed to.

Alzheimer's disease on MRI. Image Credit: Atthapon Raksthaput / Shutterstock

What is Alzheimer’s Disease?

Alzheimer’s disease is a common cause of dementia, a term used for a group of symptoms that include memory loss and difficulties with cognitive tasks such as problem-solving. As Alzheimer’s progresses, proteins build up in the brain and form neurofibrillary tangles and β-amyloid plaques (Aβ plaques). These structures result in connections between nerve cells being lost and the death of nerve cells and brain tissue. The number of chemicals responsible for transmitting signals around the brain are also depleted, meaning signals are not transmitted effectively through the brain.

Risk factors for Alzheimer’s disease are age, obesity, diabetes, and infections or inflammation in the brain.

PET Imaging

PET is a nuclear medicine procedure, meaning a small amount of radioactive material, also known as a radiopharmaceutical, radiotracer or radionuclide, is used to evaluate a particular organ’s metabolism.

MR Imaging

MR imaging uses a magnetic field and radio waves. Contrast materials administered intravenously are sometimes used to enhance the images produced by the scan.

What is Hybrid PET/MR?

PET/MR is a test combining positron emission tomography (PET) scan and magnetic resonance imaging (MRI) scan. It combines the advanced soft tissue contrast and imaging parameters of MR and the high sensitivity of PET.

MR imaging uses tissue characterization with enhanced soft tissue contrast, providing structural and functional information of the brain. MR imaging easily distinguishes between cerebral gray matter and white matter and presents the brain tissue in a 3D form. PET imaging provides the molecular and metabolic information of the brain. PET accurately charts the distribution of the tangles and plaques present in Alzheimer’s disease.

There is potential for PET/MR to be used for diagnostic classification, identifying disease stages, providing an understanding of Alzheimer’s disease pathomechanisms and also in evaluating prognosis.

Tracking the onset of Alzheimer's

Benefits of PET/MR for Alzheimer’s Disease

Combining PET and MR scans mean that patients do not have to commit to more than one scan. It also reduces the radiation burden for patients compared to those receiving positron emission tomography-computed tomography (PET-CT) scans.

Head motion can interfere with PET images but is sometimes difficult to avoid in patients with neurologic disorders. Combined PET/MR scans may mean using optical tracking equipment to correct head motion is no longer necessary.

According to a recent study, PET/MR can benefit patients with Alzheimer’s disease. It has unique benefits to improve the early and differential diagnosis. This is done through the combination of molecular and metabolic information from PET scan, and the functional and structural information from MR scan.

Risks of PET/MR for Alzheimer’s Disease

As with any medical procedure, there are a number of identified risks, including:

  • Exposure to radiation in small amounts suitable for diagnostic purposes.
  • Rare and mild allergic reactions to radiopharmaceuticals used in nuclear medicine procedures.
  • Risks to pregnant and breastfeeding women.
  • Mild pain or discomfort when the radionuclide is injected intravenously

Insulin, tranquilizers, sedatives and other medications may have a negative impact on the accuracy of a PET scan, along with the consumption of tobacco, caffeine, and alcohol, and high blood glucose levels in patients with diabetes.


Integrated PET/MR imaging for Alzheimer’s disease has proved to benefit diagnostic, prognostic and classification purposes and also increases practical convenience for patients by cutting down the number of appointments they need to attend. While PET/MR imaging does pose certain risks including radiation exposure and rare allergic reactions, its ability to provide accurate and early diagnosis of Alzheimer’s disease means that better treatment can be provided for a disease that currently lacks an effective treatment plan to stop or slow its progression.

Further Reading

Last Updated: Jul 18, 2023

Lois Zoppi

Written by

Lois Zoppi

Lois is a freelance copywriter based in the UK. She graduated from the University of Sussex with a BA in Media Practice, having specialized in screenwriting. She maintains a focus on anxiety disorders and depression and aims to explore other areas of mental health including dissociative disorders such as maladaptive daydreaming.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zoppi, Lois. (2023, July 18). Integrated PET/MR for Alzheimer’s Disease. News-Medical. Retrieved on June 18, 2024 from

  • MLA

    Zoppi, Lois. "Integrated PET/MR for Alzheimer’s Disease". News-Medical. 18 June 2024. <>.

  • Chicago

    Zoppi, Lois. "Integrated PET/MR for Alzheimer’s Disease". News-Medical. (accessed June 18, 2024).

  • Harvard

    Zoppi, Lois. 2023. Integrated PET/MR for Alzheimer’s Disease. News-Medical, viewed 18 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity